[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-001", "question": "A 58-year-old woman with hypertrophic cardiomyopathy presents with recurrent syncope despite maximum-dose beta-blocker therapy. Echocardiography reveals a resting left ventricular outflow tract (LVOT) gradient of 85 mmHg, systolic anterior motion of the mitral valve, and septal thickness of 22 mm. Coronary angiography shows a large first septal perforator arising from the left anterior descending artery supplying the basal septum. She is referred for alcohol septal ablation. During the procedure, after balloon occlusion of the septal perforator and injection of echocardiographic contrast, opacification is noted in the papillary muscle region in addition to the target septal area. What is the most appropriate next step?", "options": ["Proceed with alcohol injection as planned given adequate septal opacification", "Abort the procedure and refer for surgical myectomy", "Advance the balloon more distally and reassess contrast distribution", "Reduce the planned alcohol volume by 50% and proceed", "Switch to a different septal perforator branch if available"], "answer": "C", "answer_index": 2, "explanation": "Papillary muscle opacification during alcohol septal ablation indicates that alcohol injection would cause papillary muscle necrosis, potentially resulting in severe mitral regurgitation. The appropriate step is to reposition the balloon more distally to exclude the branch supplying the papillary muscle. Proceeding with injection (A) or reducing volume (D) risks catastrophic mitral regurgitation. Aborting immediately (B) is premature before attempting repositioning. Switching perforators (E) may be considered only if repositioning fails and another suitable branch exists.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient has hypertrophic cardiomyopathy with a significant LVOT gradient and symptoms refractory to medical therapy, making septal reduction therapy indicated. The echocardiographic contrast injection during balloon occlusion of the septal perforator shows opacification in the papillary muscle region in addition to the target septal area. This suggests that the alcohol could potentially reach the papillary muscles, which could lead to papillary muscle dysfunction and potentially mitral regurgitation, a serious complication.\n\nOption A is incorrect because while there is septal opacification, the unintended opacification of the papillary muscle region is a significant concern that warrants further evaluation before proceeding.\n\nOption B is a drastic step. While surgical myectomy is an alternative, aborting the procedure without further assessment of the contrast distribution might be premature.\n\nOption C is the most appropriate next step. Advancing the balloon more distally might help to better isolate the target septal perforator and prevent contrast from flowing into the papillary muscle region. Reassessing contrast distribution after repositioning the balloon is crucial to ensure the alcohol will be delivered safely and effectively to the intended area.\n\nOption D is a compromise but does not address the fundamental issue of potential papillary muscle involvement. Reducing the volume might mitigate the risk but does not eliminate it, and the opacification pattern still suggests a suboptimal delivery.\n\nOption E is not ideal as the primary goal is to treat the basal septum. If a different septal perforator were chosen, it might not adequately reduce the LVOT gradient if it supplies a different area of the septum.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-002", "question": "A 34-year-old man presents with progressive gait instability and cognitive decline over 18 months. Examination reveals vertical supranuclear gaze palsy, axial rigidity greater than limb rigidity, early postural instability with falls, and frontal release signs. Brain MRI shows midbrain atrophy with the 'hummingbird sign.' Genetic testing reveals a heterozygous mutation in the MAPT gene. His father died at age 45 with a similar presentation. Which tau isoform predominates in the neuropathological inclusions of this patient's condition?", "options": ["3-repeat tau (3R) exclusively", "4-repeat tau (4R) exclusively", "Mixed 3R and 4R tau in equal proportions", "Hyperphosphorylated tau without repeat domain specificity", "Truncated tau lacking the microtubule-binding domain"], "answer": "B", "answer_index": 1, "explanation": "This presentation describes progressive supranuclear palsy (PSP) phenotype associated with MAPT mutation. PSP is a 4-repeat (4R) tauopathy, with tau inclusions composed predominantly of 4R tau isoforms. Pick disease is characterized by 3R tau (A), while Alzheimer disease shows mixed 3R/4R tau (C). The tau in PSP is hyperphosphorylated but specifically 4R predominant, making (D) incomplete. Truncated tau (E) is not characteristic of PSP pathology.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with a constellation of symptoms and MRI findings highly suggestive of Progressive Supranuclear Palsy (PSP). The clinical features include progressive gait instability, cognitive decline, vertical supranuclear gaze palsy, axial rigidity, early postural instability with falls, and frontal release signs. The MRI finding of midbrain atrophy with the 'hummingbird sign' is characteristic of PSP. The genetic finding of a heterozygous mutation in the MAPT gene further supports a tauopathy. The family history of a similar presentation in his father suggests a genetic form of PSP.\n\nNeuropathologically, PSP is characterized by the accumulation of hyperphosphorylated tau protein in neuronal and glial inclusions. These inclusions are predominantly composed of 4-repeat tau isoforms (4R tau). While 3-repeat tau (3R tau) isoforms are also present in the brain, their contribution to the pathological inclusions in PSP is minimal compared to 4R tau. Other tauopathies, such as Alzheimer's disease, are characterized by the presence of both 3R and 4R tau in pathological inclusions.\n\nTherefore, in PSP, 4-repeat tau exclusively predominates in the neuropathological inclusions.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-003", "question": "A 42-year-old woman with type 1 diabetes mellitus on insulin pump therapy presents with recurrent episodes of neuroglycopenia occurring 3-4 hours postprandially despite appropriate carbohydrate counting and bolus dosing. Continuous glucose monitoring shows rapid glucose drops from 180 mg/dL to 45 mg/dL within 90 minutes after meals. Gastric emptying study is normal. Anti-insulin antibodies are markedly elevated at 85% binding (normal <5%). Which mechanism best explains her hypoglycemic episodes?", "options": ["Antibody-mediated accelerated insulin clearance causing initial hyperglycemia followed by rebound hypoglycemia", "Antibody buffering of exogenous insulin with delayed release causing prolonged insulin action", "Cross-reactivity of anti-insulin antibodies with insulin receptors causing receptor activation", "Antibody-induced insulin resistance requiring higher doses with subsequent overdosing", "Complement-mediated destruction of pancreatic alpha cells reducing glucagon counterregulation"], "answer": "B", "answer_index": 1, "explanation": "Insulin autoimmune syndrome (IAS) or exogenous insulin antibody syndrome involves high-affinity anti-insulin antibodies that bind circulating insulin, creating a 'buffer' reservoir. This causes initial postprandial hyperglycemia (insulin bound and inactive), followed by delayed hypoglycemia when insulin dissociates from antibodies hours later. This explains the pattern of post-meal hyperglycemia followed by delayed severe hypoglycemia. Accelerated clearance (A) would cause persistent hyperglycemia. Receptor cross-reactivity (C) and alpha cell destruction (E) are not mechanisms of anti-insulin antibodies.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with recurrent neuroglycopenia 3-4 hours postprandially, despite appropriate carbohydrate counting and bolus dosing. Continuous glucose monitoring shows rapid glucose drops after meals. Her anti-insulin antibodies are markedly elevated.\n\nLet's analyze the options:\n\nA. Antibody-mediated accelerated insulin clearance causing initial hyperglycemia followed by rebound hypoglycemia. Elevated anti-insulin antibodies can bind to exogenous insulin. If this binding leads to accelerated clearance, it would typically result in shorter insulin action, not prolonged hypoglycemia 3-4 hours postprandially. While some antibody interactions can be complex, accelerated clearance is less likely to cause this specific pattern of delayed hypoglycemia.\n\nB. Antibody buffering of exogenous insulin with delayed release causing prolonged insulin action. This mechanism is consistent with the observed symptoms. Elevated anti-insulin antibodies can act as a buffer, binding to the injected insulin. This binding can delay the dissociation of insulin from the antibody, effectively prolonging its action. When the insulin eventually dissociates, it can lead to a more sustained and potentially excessive insulin effect, causing hypoglycemia several hours after the meal. The rapid glucose drops seen on CGM also support a delayed but potent insulin effect.\n\nC. Cross-reactivity of anti-insulin antibodies with insulin receptors causing receptor activation. While antibodies can sometimes cross-react, it's less common for anti-insulin antibodies to directly activate insulin receptors in a way that causes recurrent hypoglycemia. The primary role of anti-insulin antibodies in this context is usually related to the exogenous insulin itself.\n\nD. Antibody-induced insulin resistance requiring higher doses with subsequent overdosing. Insulin resistance would typically lead to hyperglycemia, requiring *higher* insulin doses to achieve normoglycemia. If the patient were overdosing due to resistance, the hypoglycemia would likely be more immediate and less predictable in its timing relative to meals. The fact that she is counting carbohydrates and bolusing appropriately suggests that the issue is not simply resistance leading to overdosing.\n\nE. Complement-mediated destruction of pancreatic alpha cells reducing glucagon counterregulation. This mechanism would affect endogenous insulin and glucagon production. The patient is on an insulin pump, implying type 1 diabetes, where endogenous insulin production is absent. Furthermore, complement-mediated destruction of alpha cells is not directly related to anti-insulin antibodies against exogenous insulin.\n\nConsidering the elevated anti-insulin antibodies and the pattern of delayed postprandial hypoglycemia, option B provides the most plausible explanation. The antibodies bind to the exogenous insulin, creating a depot effect, and then release it slowly, leading to prolonged and potentially excessive insulin action.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-004", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy-defibrillator (CRT-D) presents for device interrogation. He reports improved functional capacity since implantation 6 months ago. Interrogation reveals 94% biventricular pacing. However, the device electrograms show that during intrinsic AV conduction, the LV lead captures occurs 40 ms after RV lead capture, and during biventricular pacing, LV capture occurs 15 ms before RV capture. His current AV delay is programmed at 120 ms sensed/150 ms paced. What programming change would most likely optimize his cardiac resynchronization?", "options": ["Shorten the AV delay to 80 ms sensed/110 ms paced", "Lengthen the AV delay to 180 ms sensed/210 ms paced", "Program VV delay with RV preceding LV by 40 ms", "Program VV delay with LV preceding RV by 30 ms", "Enable automatic AV and VV optimization algorithm"], "answer": "A", "answer_index": 0, "explanation": "The electrogram findings indicate that intrinsic conduction results in significant LV delay (LV activates 40 ms after RV), consistent with left bundle branch block pattern. During BiV pacing, LV leads RV by only 15 ms, suggesting suboptimal resynchronization. The key issue is that with a 120 ms AV delay, there may be fusion with intrinsic conduction compromising true biventricular capture. Shortening the AV delay ensures complete ventricular capture by the device before intrinsic conduction, maximizing resynchronization benefit. Programming RV to precede LV (C) would worsen the native LBBB pattern. Lengthening AV delay (B) would increase fusion. While automatic algorithms (E) exist, the specific findings here indicate the need for shorter AV delay.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The question describes a patient with ischemic cardiomyopathy and CRT-D who has improved functional capacity. The interrogation reveals high biventricular pacing percentage. The key information for optimizing CRT is the timing of ventricular activation relative to intrinsic conduction and during pacing.\n\nDuring intrinsic AV conduction, LV lead capture occurs 40 ms after RV lead capture. This suggests that the RV lead is capturing the ventricle earlier than the LV lead. In CRT, the goal is to resynchronize ventricular contraction. If the intrinsic conduction leads to a delay between RV and LV activation, this is not ideal.\n\nDuring biventricular pacing, LV capture occurs 15 ms before RV capture. This is the opposite of what is desired for optimal resynchronization, where the pacing should ideally mimic a normal physiological sequence or correct the underlying electrical delay.\n\nThe current AV delay is programmed at 120 ms sensed/150 ms paced. This is the delay between atrial activation and ventricular pacing.\n\nLet's analyze the options:\n\nA. Shorten the AV delay to 80 ms sensed/110 ms paced: Shortening the AV delay would lead to earlier ventricular pacing. This might not address the specific issue of LV preceding RV capture during pacing.\n\nB. Lengthen the AV delay to 180 ms sensed/210 ms paced: Lengthening the AV delay would lead to later ventricular pacing. Similar to shortening, this doesn't directly address the VV interval.\n\nC. Program VV delay with RV preceding LV by 40 ms: The VV delay refers to the interval between RV and LV pacing. The current pacing shows LV preceding RV by 15 ms. If RV precedes LV by 40 ms, this would mean RV pacing occurs 40 ms before LV pacing. This aims to correct the observed LV preceding RV pacing. The 40 ms value is derived from the intrinsic conduction where LV capture occurs 40 ms after RV lead capture, suggesting a potential physiological delay that CRT aims to overcome or mimic. By pacing RV first, it might help to initiate depolarization in a way that leads to more synchronous activation.\n\nD. Program VV delay with LV preceding RV by 30 ms: This would further exaggerate the observed LV preceding RV capture during pacing, which is likely suboptimal.\n\nE. Enable automatic AV and VV optimization algorithm: While automatic optimization algorithms can be useful, the question asks for a specific programming change that would *most likely* optimize his cardiac resynchronization based on the provided electrogram findings. The observed pacing sequence (LV before RV) is a direct target for correction.\n\nConsidering the electrogram findings:\n- Intrinsic conduction: RV lead capture 40 ms before LV lead capture. This implies that the native conduction system, when stimulated by the RV lead, results in a delay in LV activation.\n- Biventricular pacing: LV capture 15 ms before RV capture. This is the opposite of the intrinsic conduction and is likely contributing to suboptimal resynchronization.\n\nThe goal of CRT is to coordinate ventricular contraction. If LV is pacing before RV, it's creating an unnatural sequence. The intrinsic conduction shows a delay in LV activation relative to RV. To optimize, we want to pace in a way that minimizes this delay or creates a more physiological sequence.\n\nOption C suggests programming the VV delay with RV preceding LV by 40 ms. This directly addresses the observed pacing abnormality where LV precedes RV. By pacing the RV first, it might allow for a more natural spread of depolarization towards the LV, or it might be programmed to compensate for the intrinsic delay observed. The 40 ms is a significant interval and could be chosen to mimic or correct the observed intrinsic delay.\n\nLet's re-evaluate the intrinsic conduction. \"during intrinsic AV conduction, the LV lead captures occurs 40 ms after RV lead capture\". This means that when the heart is beating intrinsically, the RV lead is sensing something that leads to capture, and then 40 ms later, the LV lead captures. This implies that the RV lead is positioned in an area that depolarizes earlier, and the LV lead is in an area that depolarizes later.\n\nDuring biventricular pacing, \"LV capture occurs 15 ms before RV capture\". This is the opposite and is suboptimal. We want to correct this.\n\nIf we program RV to pace 40 ms before LV (Option C), we are essentially trying to create a sequence where the RV is stimulated first, and then the LV is stimulated 40 ms later. This is attempting to correct the current pacing sequence where LV precedes RV. The 40 ms value is derived from the intrinsic conduction, suggesting it might be a relevant interval to consider for pacing.\n\nLet's consider the goal of CRT. It's to synchronize the ventricles. If the intrinsic conduction has a delay between RV and LV activation, and the pacing is causing LV to activate before RV, then we need to adjust the pacing.\n\nOption C: Program VV delay with RV preceding LV by 40 ms. This means RV is paced, and then 40 ms later, LV is paced. This directly counteracts the current pacing where LV precedes RV. The 40 ms is a significant interval and could be chosen to try and achieve better synchrony, potentially by mimicking or correcting the intrinsic delay.\n\nLet's think about the intrinsic conduction again. \"LV lead captures occurs 40 ms after RV lead capture\". This means that the RV lead is sensing something that triggers capture, and then 40 ms later, the LV lead captures. This implies that the RV is depolarizing earlier than the LV.\n\nDuring pacing, \"LV capture occurs 15 ms before RV capture\". This is the opposite.\n\nTo optimize CRT, we want to ensure that the ventricles contract in a coordinated manner. If LV is pacing before RV, it's creating an unnatural sequence. We want to correct this.\n\nOption C suggests RV preceding LV by 40 ms. This means RV is paced, then 40 ms later, LV is paced. This is a direct attempt to correct the current pacing sequence where LV precedes RV. The 40 ms is a significant interval and could be chosen to try and achieve better synchrony, potentially by mimicking or correcting the intrinsic delay.\n\nLet's consider the possibility that the intrinsic conduction is showing a delay that CRT is meant to overcome. However, the pacing is creating an even worse situation (LV before RV).\n\nIf RV captures 40 ms after intrinsic AV conduction, and LV captures 15 ms before RV during pacing, we need to adjust the pacing.\n\nOption C: Program VV delay with RV preceding LV by 40 ms. This means RV is paced, and then 40 ms later, LV is paced. This is a direct attempt to correct the current pacing sequence where LV precedes RV. The 40 ms is a significant interval and could be chosen to try and achieve better synchrony, potentially by mimicking or correcting the intrinsic delay.\n\nLet's consider the goal of CRT. It's to synchronize the ventricles. If LV is pacing before RV, it's creating an unnatural sequence. We want to correct this.\n\nOption C: Program VV delay with RV preceding LV by 40 ms. This means RV is paced, and then 40 ms later, LV is paced. This is a direct attempt to correct the current pacing sequence where LV precedes RV. The 40 ms is a significant interval and could be chosen to try and achieve better synchrony, potentially by mimicking or correcting the intrinsic delay.\n\nThe intrinsic conduction shows RV depolarizing earlier than LV. The pacing shows LV depolarizing earlier than RV. To optimize, we want to correct the pacing. Programming RV to pace before LV is the correct direction. The 40 ms is a plausible interval to try and achieve synchrony, possibly by trying to mimic the intrinsic delay or correct the current reversed pacing.\n\nThe final answer is $\\boxed{C}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-005", "question": "A 29-year-old woman presents with acute onset of right-sided weakness and aphasia. CT head is negative for hemorrhage. CT angiography reveals complete occlusion of the left middle cerebral artery M1 segment. CT perfusion shows a small core infarct (8 mL) with large penumbra (95 mL mismatch). Her NIHSS is 18. Time last known well is 2 hours ago. She has a history of antiphospholipid syndrome with prior deep vein thrombosis, currently on warfarin with INR of 3.2. What is the most appropriate acute intervention?", "options": ["Intravenous alteplase followed by mechanical thrombectomy", "Mechanical thrombectomy alone without intravenous thrombolysis", "Intravenous alteplase alone with close monitoring", "Administer 4-factor prothrombin complex concentrate then IV alteplase and thrombectomy", "Anticoagulation reversal with idarucizumab followed by mechanical thrombectomy"], "answer": "B", "answer_index": 1, "explanation": "This patient has a large vessel occlusion with favorable perfusion imaging (small core, large penumbra) within the thrombectomy window. However, her INR of 3.2 is a contraindication to IV alteplase (INR >1.7 is exclusion criterion). Mechanical thrombectomy is not contraindicated by anticoagulation status and should be performed emergently. IV alteplase (A, C) is contraindicated with therapeutic anticoagulation. PCC reversal followed by alteplase (D) delays definitive treatment and alteplase remains relatively contraindicated even after reversal. Idarucizumab (E) reverses dabigatran, not warfarin.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The patient presents with a large territory ischemic stroke (NIHSS 18, large penumbra) with a confirmed large vessel occlusion (M1 MCA). She is within the time window for reperfusion therapy.\n\nOption A: Intravenous alteplase is indicated for acute ischemic stroke within 4.5 hours of symptom onset, provided there are no contraindications. Mechanical thrombectomy is indicated for large vessel occlusions in the anterior circulation within 6 hours, and potentially up to 24 hours in select patients based on imaging. Given the large penumbra and the M1 occlusion, both therapies are likely beneficial.\n\nOption B: Mechanical thrombectomy alone might be considered if there were contraindications to IV alteplase. However, the patient's INR of 3.2 is a relative contraindication to IV alteplase, but not an absolute one, and can be managed.\n\nOption C: Intravenous alteplase alone might be insufficient given the large vessel occlusion and the potential benefit of mechanical thrombectomy in restoring flow more effectively.\n\nOption D: The patient is on warfarin with an INR of 3.2. While this is elevated, it is not an absolute contraindication to IV alteplase, especially if the benefits outweigh the risks. Reversing the INR with 4-factor PCC would be considered if the INR was significantly higher (e.g., > 1.7 for IV alteplase) or if there was active bleeding. However, the INR of 3.2 is within the range where IV alteplase can be administered with caution, and the decision to reverse would depend on the specific protocol and risk assessment. Given the time-sensitive nature of reperfusion, administering PCC first might delay treatment. However, some guidelines suggest that if the INR is >1.7, it should be reversed before IV alteplase. The question asks for the *most appropriate* intervention. Given the large penumbra and M1 occlusion, reperfusion is critical. If the INR is considered too high for IV alteplase, then mechanical thrombectomy would be the next best step, potentially after some INR management. However, the prompt implies a need for both.\n\nOption E: Idarucizumab is a reversal agent for dabigatran, a direct thrombin inhibitor, not warfarin. Therefore, this option is incorrect.\n\nRevisiting Option D: The INR of 3.2 is a relative contraindication to IV alteplase. Many protocols would consider reversing the INR to <1.7 before administering IV alteplase. If the INR is reversed, then both IV alteplase and mechanical thrombectomy would be appropriate. The question asks for the *most appropriate acute intervention*. Given the large vessel occlusion and the potential for significant neurological deficit, aggressive reperfusion is warranted. If the INR is a barrier to IV alteplase, then addressing the INR and proceeding with both therapies is the most comprehensive approach. However, the wording \"Administer 4-factor prothrombin complex concentrate then IV alteplase and thrombectomy\" suggests a sequential approach.\n\nLet's re-evaluate the contraindications for IV alteplase. An INR > 1.7 is a contraindication. Therefore, the INR of 3.2 necessitates reversal before IV alteplase. After reversal, both IV alteplase and mechanical thrombectomy are indicated.\n\nConsidering the options again:\nA. IV alteplase followed by mechanical thrombectomy - This is appropriate if there are no contraindications to IV alteplase. The INR of 3.2 is a contraindication.\nB. Mechanical thrombectomy alone without intravenous thrombolysis - This would be considered if IV alteplase is absolutely contraindicated.\nC. Intravenous alteplase alone with close monitoring - Insufficient for LVO.\nD. Administer 4-factor prothrombin complex concentrate then IV alteplase and thrombectomy - This addresses the INR contraindication and then proceeds with both indicated therapies. This seems to be the most comprehensive and appropriate approach given the patient's presentation and history.\nE. Anticoagulation reversal with idarucizumab followed by mechanical thrombectomy - Incorrect reversal agent.\n\nTherefore, the most appropriate acute intervention is to address the INR and then proceed with both reperfusion strategies.\n\nThe final answer is $\\boxed{D}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-006", "question": "A 55-year-old man with severe persistent asthma on high-dose inhaled corticosteroids, long-acting beta-agonist, long-acting muscarinic antagonist, and monthly omalizumab presents with continued poor control. Spirometry shows FEV1 45% predicted with 15% bronchodilator response. Laboratory studies reveal blood eosinophils 450 cells/μL, total IgE 850 IU/mL, and FeNO 55 ppb. Sputum analysis shows 8% eosinophils. Despite confirmed adherence and proper inhaler technique, he has had 4 exacerbations requiring systemic corticosteroids in the past year. Which biologic switch would most likely provide additional benefit?", "options": ["Dupilumab targeting IL-4 receptor alpha", "Benralizumab targeting IL-5 receptor alpha", "Mepolizumab targeting IL-5", "Tezepelumab targeting thymic stromal lymphopoietin", "Continue omalizumab with addition of low-dose oral corticosteroids"], "answer": "D", "answer_index": 3, "explanation": "This patient has severe eosinophilic asthma failing omalizumab (anti-IgE) therapy despite elevated biomarkers (eosinophils, FeNO). Tezepelumab targets TSLP, an epithelial cytokine upstream of multiple inflammatory pathways (Th2, ILC2), and has demonstrated efficacy regardless of baseline eosinophil count or IgE levels, including in patients who failed other biologics. While anti-IL-5/IL-5R agents (B, C) and dupilumab (A) target eosinophilic inflammation, tezepelumab's upstream mechanism may provide benefit when anti-IgE therapy has failed despite persistent type 2 inflammation. Adding oral corticosteroids (E) increases adverse effects without addressing the underlying inflammatory pathway.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient has severe persistent asthma with features suggestive of eosinophilic inflammation (blood eosinophils 450 cells/μL, sputum eosinophils 8%, FeNO 55 ppb) and a history of frequent exacerbations despite maximal conventional therapy and omalizumab. Omalizumab targets IgE and is effective in allergic asthma, but this patient's eosinophil counts and FeNO suggest a different inflammatory pathway is driving his uncontrolled asthma.\n\nLet's analyze the options:\n\nA. Dupilumab targets the IL-4 receptor alpha subunit, inhibiting signaling of both IL-4 and IL-13. These cytokines are key drivers of Type 2 inflammation, which is associated with eosinophilic asthma. Given the patient's eosinophilic markers, dupilumab is a strong candidate.\n\nB. Benralizumab targets the IL-5 receptor alpha subunit on eosinophils, leading to their depletion. IL-5 is a crucial cytokine for eosinophil survival, activation, and recruitment. This would be beneficial for an eosinophilic phenotype.\n\nC. Mepolizumab targets IL-5 directly, reducing eosinophil counts. Similar to benralizumab, it addresses the IL-5 pathway involved in eosinophilic asthma.\n\nD. Tezepelumb targets thymic stromal lymphopoietin (TSLP), an upstream cytokine that drives Type 2 inflammation and can influence eosinophilic and other inflammatory pathways in asthma. It has shown efficacy in severe asthma, including in patients with eosinophilic phenotypes.\n\nE. Continuing omalizumab and adding low-dose oral corticosteroids is an option, but the question asks for a *biologic switch* that would *most likely provide additional benefit*. Oral corticosteroids have significant side effects with long-term use, and the goal is to avoid or reduce their use. While omalizumab targets IgE, the patient's eosinophilic markers suggest other pathways are more dominant.\n\nComparing options A, B, C, and D:\nThe patient has elevated blood eosinophils, sputum eosinophils, and FeNO, all indicating eosinophilic inflammation. Dupilumab (targeting IL-4/IL-13) and benralizumab/mepolizumab (targeting IL-5) are well-established treatments for eosinophilic asthma. Tezepelumab targets TSLP, which is upstream of IL-4, IL-5, and IL-13, and has shown broad efficacy in severe asthma, including eosinophilic phenotypes.\n\nHowever, the question asks for the *most likely* additional benefit. Dupilumab has demonstrated significant efficacy in reducing exacerbations and improving lung function in patients with moderate-to-severe eosinophilic asthma, particularly those with elevated FeNO. While benralizumab and mepolizumab are also effective for eosinophilic asthma, dupilumab's mechanism targeting both IL-4 and IL-13 may offer a broader impact on Type 2 inflammation. Tezepelumab is also a strong contender, but dupilumab has a more established track record specifically for eosinophilic asthma with elevated FeNO.\n\nConsidering the provided clinical data, particularly the elevated FeNO and eosinophils, dupilumab is a highly appropriate choice for further treatment.\n\nThe final answer is $\\boxed{A}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-007", "question": "A 48-year-old woman is brought to the emergency department after being found unresponsive at home. She has a history of depression. On examination, she is comatose with pinpoint pupils, respiratory rate of 6/min, temperature 35.8°C, and blood pressure 90/60 mmHg. ECG shows QRS duration of 145 ms with a terminal R wave in aVR of 4 mm. After securing the airway and administering naloxone without response, what is the most appropriate next intervention?", "options": ["Intravenous flumazenil 0.2 mg", "Intravenous sodium bicarbonate bolus targeting serum pH 7.50-7.55", "Intravenous lipid emulsion 20% bolus", "Intravenous glucagon 5 mg bolus", "Emergent hemodialysis"], "answer": "B", "answer_index": 1, "explanation": "The clinical presentation (coma, miosis, respiratory depression, hypotension) with ECG findings of QRS widening >100 ms and terminal R wave in aVR >3 mm is classic for tricyclic antidepressant (TCA) toxicity. The sodium channel blockade causing cardiac toxicity is treated with sodium bicarbonate, which increases extracellular sodium (overcoming channel blockade) and alkalinizes serum (increasing protein binding of TCA). Target pH is 7.50-7.55. Flumazenil (A) is contraindicated as it may precipitate seizures in TCA overdose. Lipid emulsion (C) is second-line. Glucagon (D) is for beta-blocker toxicity. Hemodialysis (E) is ineffective for TCAs due to high protein binding and large volume of distribution.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The patient presents with coma, pinpoint pupils, bradycardia (implied by low respiratory rate and likely low heart rate given hypotension), hypothermia, and hypotension. The ECG findings of a prolonged QRS duration (145 ms) and a terminal R wave in aVR are highly suggestive of a tricyclic antidepressant (TCA) overdose.\n\nLet's analyze the options:\n\nA. Intravenous flumazenil 0.2 mg: Flumazenil is a benzodiazepine antagonist. While the patient has a history of depression, there's no indication of benzodiazepine overdose. Furthermore, flumazenil can precipitate seizures in patients with mixed overdoses or underlying conditions, making it generally contraindicated in undifferentiated comatose patients with suspected TCA overdose.\n\nB. Intravenous sodium bicarbonate bolus targeting serum pH 7.50-7.55: Sodium bicarbonate is the cornerstone of management for significant TCA overdose, particularly when there are ECG abnormalities like QRS widening. It works by increasing serum pH, which reduces the binding of TCAs to sodium channels in the myocardium and brain, thereby improving cardiac conduction and reducing CNS toxicity. The ECG findings strongly support this diagnosis and the need for bicarbonate.\n\nC. Intravenous lipid emulsion 20% bolus: Intravenous lipid emulsion (ILE) is indicated for severe toxicity from lipophilic drugs, including TCAs, especially when there is cardiovascular collapse or refractory arrhythmias. While it's a potential treatment for TCA overdose, sodium bicarbonate is typically the first-line intervention for ECG abnormalities suggestive of TCA toxicity.\n\nD. Intravenous glucagon 5 mg bolus: Glucagon is primarily used for beta-blocker or calcium channel blocker overdose. It is not indicated for TCA overdose.\n\nE. Emergent hemodialysis: Hemodialysis is generally not effective for removing TCAs from the body due to their large volume of distribution and protein binding. It is reserved for specific situations like severe renal failure or certain intoxicants that are dialyzable.\n\nGiven the strong suspicion of TCA overdose based on the clinical presentation and ECG findings, intravenous sodium bicarbonate is the most appropriate immediate intervention to address the cardiotoxicity and CNS depression.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-008", "question": "A 62-year-old man with longstanding type 2 diabetes presents with a 6-month history of burning pain and numbness in his feet, now extending to mid-calf. Examination reveals absent ankle reflexes, reduced pinprick and vibration sense to the knees bilaterally, and mild weakness of toe extension. Nerve conduction studies show absent sural sensory responses, reduced peroneal motor amplitudes with mildly slowed conduction velocities, and prolonged F-wave latencies. Hemoglobin A1c is 7.2%. He is started on duloxetine with minimal improvement after 8 weeks. Gabapentin is added and titrated to 1800 mg daily with partial response. Which additional intervention has the strongest evidence for further symptomatic improvement?", "options": ["Alpha-lipoic acid 600 mg IV daily for 3 weeks", "Topical capsaicin 8% patch application to affected areas", "Spinal cord stimulation trial", "Transcutaneous electrical nerve stimulation (TENS)", "Acupuncture twice weekly for 12 weeks"], "answer": "C", "answer_index": 2, "explanation": "This patient has painful diabetic peripheral neuropathy refractory to first-line (duloxetine) and second-line (gabapentin) pharmacotherapy. Spinal cord stimulation (SCS) has Level 1 evidence from randomized controlled trials (SENZA-PDN, others) demonstrating significant pain reduction in refractory painful diabetic neuropathy, with FDA approval for this indication. Alpha-lipoic acid (A) has modest evidence primarily from European studies. High-concentration capsaicin (B) provides temporary relief but evidence in diabetic neuropathy is limited. TENS (D) and acupuncture (E) have weaker evidence compared to SCS for refractory cases.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The question describes a patient with diabetic peripheral neuropathy (DPN) experiencing neuropathic pain. The patient has already been treated with duloxetine and gabapentin with partial response. We need to identify the intervention with the strongest evidence for further symptomatic improvement in this context.\n\nLet's evaluate the options:\n\nA. Alpha-lipoic acid 600 mg IV daily for 3 weeks: Intravenous alpha-lipoic acid has shown some benefit in improving symptoms of DPN, particularly in reducing pain and improving nerve conduction. However, the evidence for IV administration for acute symptomatic relief is generally considered moderate, and oral forms are more commonly used for long-term management.\n\nB. Topical capsaicin 8% patch application to affected areas: High-concentration (8%) topical capsaicin patches have demonstrated significant efficacy in reducing neuropathic pain in DPN. Multiple randomized controlled trials support its use, showing substantial pain relief in a significant proportion of patients. It acts by desensitizing nociceptive C-fibers.\n\nC. Spinal cord stimulation trial: Spinal cord stimulation (SCS) is an invasive neuromodulation technique that can be effective for chronic refractory neuropathic pain, including DPN. However, it is typically considered a later-line treatment after conservative measures have failed, and a trial is a prerequisite for permanent implantation. While it can be effective, it's a more involved intervention than topical treatments.\n\nD. Transcutaneous electrical nerve stimulation (TENS): TENS is a non-invasive modality that can provide temporary pain relief for neuropathic pain. However, the evidence supporting its long-term efficacy in DPN is generally considered weaker and less consistent compared to other pharmacological or interventional treatments.\n\nE. Acupuncture twice weekly for 12 weeks: Acupuncture is an alternative therapy that some patients find helpful for neuropathic pain. However, the evidence base for its effectiveness in DPN is mixed and generally not as robust as for established pharmacological treatments or high-concentration topical agents.\n\nComparing the options, high-concentration topical capsaicin (8% patch) has strong evidence from multiple randomized controlled trials demonstrating significant pain relief in patients with DPN who have not responded adequately to other treatments. It is a targeted, non-systemic treatment that can be effective for localized neuropathic pain. While IV alpha-lipoic acid has some evidence, topical capsaicin often shows more pronounced and consistent symptomatic relief for pain in DPN. Spinal cord stimulation is a more invasive option for refractory pain, and TENS and acupuncture have weaker evidence bases for DPN compared to topical capsaicin.\n\nThe final answer is $\\boxed{B}$."}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-009", "question": "A 71-year-old man with COPD GOLD stage III is hospitalized for acute exacerbation. On day 3, despite antibiotics, systemic corticosteroids, and scheduled bronchodilators, he remains dyspneic with respiratory rate 28/min, accessory muscle use, and ABG showing pH 7.31, PaCO2 58 mmHg, PaO2 55 mmHg on 4L nasal cannula. He is alert and cooperative. Bilevel positive airway pressure (BiPAP) is initiated at IPAP 12/EPAP 5 cm H2O. After 2 hours, repeat ABG shows pH 7.29, PaCO2 62 mmHg. He remains tachypneic but is tolerating the mask. What is the most appropriate next step?", "options": ["Increase IPAP to 18 cm H2O and reassess in 1-2 hours", "Proceed with endotracheal intubation and mechanical ventilation", "Add heliox (helium-oxygen mixture) to the BiPAP circuit", "Switch to high-flow nasal cannula at 60 L/min", "Increase EPAP to 10 cm H2O while maintaining IPAP"], "answer": "A", "answer_index": 0, "explanation": "The patient has acute hypercapnic respiratory failure from COPD exacerbation with initial NIV settings that are inadequate (worsening hypercapnia). The driving pressure (IPAP-EPAP = 7 cm H2O) is insufficient for adequate ventilation. Increasing IPAP to 18 cm H2O (driving pressure 13 cm H2O) will augment tidal volume and improve CO2 clearance. Intubation (B) is premature as he is tolerating NIV and is not deteriorating clinically. Heliox (C) reduces airway resistance but doesn't address ventilation. HFNC (D) provides less ventilatory support than BiPAP for hypercapnic failure. Increasing EPAP alone (E) would reduce driving pressure further, worsening ventilation.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient has persistent hypercapnic respiratory failure despite initial BiPAP therapy. His pH has dropped slightly, and his PaCO2 has increased, indicating worsening ventilation. While he is tolerating the mask, the current BiPAP settings are not effectively clearing CO2.\n\nOption A: Increasing the IPAP will increase the tidal volume and improve CO2 removal. This is a reasonable next step to optimize BiPAP before considering more invasive measures.\n\nOption B: Endotracheal intubation and mechanical ventilation are indicated for severe respiratory failure that is unresponsive to non-invasive ventilation, or if the patient develops signs of impending respiratory arrest, hemodynamic instability, or inability to tolerate BiPAP. While the patient is not improving, he is still alert, cooperative, and tolerating the mask, so intubation is not immediately necessary.\n\nOption C: Heliox can reduce the work of breathing in some obstructive lung diseases by decreasing gas density, but it is not a primary treatment for hypercapnic respiratory failure and its benefit in this scenario is uncertain.\n\nOption D: High-flow nasal cannula (HFNC) can provide some positive pressure and improve oxygenation, but it is generally less effective than BiPAP for significant hypercapnic respiratory failure.\n\nOption E: Increasing EPAP primarily improves oxygenation by increasing intrinsic PEEP and preventing alveolar collapse. While oxygenation is also a concern (PaO2 55 mmHg), the primary issue is hypercapnia, which is better addressed by increasing the pressure support (IPAP).\n\nGiven the persistent hypercapnia and the patient's ability to tolerate BiPAP, optimizing the current therapy by increasing the pressure support (IPAP) is the most appropriate next step.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-010", "question": "A 38-year-old woman presents with palpitations and near-syncope. ECG shows a regular wide complex tachycardia at 220 bpm with RBBB morphology, northwest axis, and AV dissociation. She is hemodynamically stable with blood pressure 105/70 mmHg. Adenosine 12 mg IV is administered without effect. Procainamide infusion is started, and after 8 minutes (750 mg administered), the rhythm converts to sinus. Post-conversion ECG reveals sinus rhythm with a short PR interval (100 ms), delta waves, and QRS duration of 140 ms with positive delta wave in V1. Which electrophysiologic finding would most strongly support proceeding with catheter ablation rather than medical management?", "options": ["Accessory pathway effective refractory period of 270 ms", "Inducible orthodromic atrioventricular reentrant tachycardia", "Accessory pathway located in the left lateral position", "Shortest pre-excited RR interval during induced atrial fibrillation of 220 ms", "Decremental conduction properties of the accessory pathway"], "answer": "D", "answer_index": 3, "explanation": "This patient has Wolff-Parkinson-White syndrome with documented antidromic AVRT (wide complex tachycardia with AV dissociation, RBBB morphology suggesting left-sided pathway). The most important risk stratification parameter is the shortest pre-excited RR interval (SPERRI) during atrial fibrillation, which reflects the accessory pathway's ability to conduct rapid atrial rates to the ventricle. SPERRI ≤250 ms indicates high-risk pathway capable of conducting AF at rates that could degenerate to ventricular fibrillation, strongly favoring ablation. Accessory pathway ERP (A) is less predictive than SPERRI. Inducible orthodromic AVRT (B) and pathway location (C) don't indicate sudden death risk. Decremental properties (E) actually suggest lower risk.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "The question describes a patient with a history suggestive of Wolff-Parkinson-White (WPW) syndrome, presenting with a wide complex tachycardia. The post-conversion ECG findings of a short PR interval, delta waves, and prolonged QRS duration are classic for WPW. The key to choosing the best option for proceeding with catheter ablation lies in identifying factors that predict a higher risk of sudden cardiac death or life-threatening arrhythmias.\n\nLet's analyze the options:\n\nA. Accessory pathway effective refractory period of 270 ms: A shorter effective refractory period (ERP) of the accessory pathway is associated with a higher risk of rapid ventricular rates during atrial fibrillation, as the pathway can conduct faster. A longer ERP (like 270 ms) might suggest a lower risk in this regard, making ablation less urgent compared to other high-risk features.\n\nB. Inducible orthodromic atrioventricular reentrant tachycardia: While inducible orthodromic AVRT is a common finding in WPW, its inducibility alone doesn't necessarily mandate ablation over medical management, especially if the patient is asymptomatic or has low-risk features. The patient in the scenario *did* have a wide complex tachycardia, which is often due to antidromic AVRT or atrial fibrillation with rapid ventricular response through the accessory pathway.\n\nC. Accessory pathway located in the left lateral position: The location of the accessory pathway can influence the morphology of the QRS during pre-excitation and the tachycardia, but it's not the primary determinant of risk for sudden cardiac death.\n\nD. Shortest pre-excited RR interval during induced atrial fibrillation of 220 ms: This is a critical finding. A shortest pre-excited RR interval of 220 ms during induced atrial fibrillation indicates that the accessory pathway can conduct very rapidly (approximately 273 bpm). This rapid conduction during atrial fibrillation can lead to ventricular fibrillation and sudden cardiac death. A shortest pre-excited RR interval of less than 250 ms is considered a high-risk feature that strongly favors catheter ablation.\n\nE. Decremental conduction properties of the accessory pathway: Decremental conduction means that the conduction velocity slows down as the rate of stimulation increases. This is a characteristic of the AV node, not typically of accessory pathways. If an accessory pathway exhibits decremental properties, it might suggest a lower risk of rapid conduction, making ablation less urgent.\n\nConsidering the options, the shortest pre-excited RR interval during induced atrial fibrillation of 220 ms (option D) is the most significant electrophysiologic finding that strongly supports proceeding with catheter ablation due to the high risk of life-threatening arrhythmias.\n\nThe answer is (D)"}]